---
$id: https://graph.org.ai/products/commodity/51111654
$type: Product
source: UNSPSC
code: "51111654"
title: "Raltitrexed"
class: "51111600"
classTitle: "Antimetabolites"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Raltitrexed

**UNSPSC Code**: 51111654
**Class**: [Antimetabolites](Antimetabolites.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a thymidylate synthase inhibitor and folate antagonist with the molecular formula C21H22N4O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FCB9EGG971, chemically known as n-(5-(n-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-n-methylamino)-2-thenoyl)-l-glutamic acid but generally known as raltitrexed, which bears US NIH Compound Identifier 104758. European Medicines Agency schedules Raltitrexed in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10244MIG. The term RALTITREXED is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules raltitrexed in its Anatomical Therapeutic Chemical (ATC) Classification. RALTITREXED is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule raltitrexed under HS 29349990 and SITC 51579. As of Q4 2014, RALTITREXED remains the US FDA Preferred Term for this commodity. Raltitrexed bears US NLM identifiers UMLS ID C0677667 and NCI Concept Code C1804. SMILES: S1C(N(CC2CC3C([NH]C(NC3=O)C)CC2)C)CCC1C(=O)NC(CCC(=O)O)C(=O)O.

